Academic Journal
Q2Respiratory Investigation
About Respiratory Investigation
About Respiratory Investigation
Respiratory Investigation is a peer-reviewed scholarly journal published by 28 (Netherlands). It focuses on Q2. Publication coverage spans 2012-2026.
Key indicators: ISSN 2212-5345, 2212-5353; H-index 48.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (48): 48 articles have each received at least 48 citations, indicating growing recognition.
Publishing in Respiratory Investigation
When considering this journal, verify its current indexing status, editorial board, and recent publications to ensure it meets your needs for visibility and credibility.
- Scope fit: Confirm your research aligns with Q2. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Respiratory Investigation?
2212-5345, 2212-5353.
Who publishes Respiratory Investigation?
28.
What are Respiratory Investigation's metrics?
H-index 48.
Where do I submit to Respiratory Investigation?
Via the official website.
Is Respiratory Investigation peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis; Chronic Obstructive Pulmonary Disease (COPD) Research; Lung Cancer Diagnosis and Treatment; Asthma and respiratory diseases; Lung Cancer Treatments and Mutations; Respiratory Support and Mechanisms.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
3,000.00 USD; 2,810.00 EUR; 2,400.00 GBP; 372,090.00 JPY
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Salivary alpha-amylase as a biomarker for obstructive sleep apnea severity and continuous positive airway pressure adherence: A cluster-based phenotyping approach
Kazuyuki Ohmura, Toru Shirahata, Tatsuyuki Miyashita, Yoshitaka Uchida et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101520Nintedanib for progressive pulmonary fibrosis associated with sarcoidosis: a retrospective preliminary observational report
Toru Arai, Masaki Hirose, Takehiko Kobayashi, Ryouta Shintani et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101513Lung microbiome alterations in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis: A systematic review with insights into microbiome–host interactions and the gut–lung axis
Sanjukta Dasgupta, Sushmita Roychowdhury, Koel Chaudhury
2026-11 · DOI: 10.1016/j.resinv.2026.101515Prevalence and predictors of pulmonary hypertension in patients with progressive pulmonary fibrosis: A retrospective study
Kenichiro Takeda, Ayako Shigeta, Keiko Yamamoto, Akira Naito et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101512Smoking status and adherence to diagnostic follow-up after community-based low-dose CT screening
Takamasa Hotta, Megumi Hamaguchi, Tamio Okimoto
2026-11 · DOI: 10.1016/j.resinv.2026.101518Gefitinib response after acquisition of C797S following first-line osimertinib in EGFR L858R/E709K-mutated non-small cell lung cancer: A case report
Yuto Tagawa, Seigo Katakura, Tetsuro Kondo, Haruhiro Saito et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101508Relationship between physical activity and muscle mass or quality in chronic obstructive pulmonary disease patients
Seigo Sasaki, Yoshiaki Minakata, Hideya Ono, Yusuke Murakami et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101484Association of liver fibrosis with incident chronic obstructive pulmonary disease
Jialiang He
2026-11 · DOI: 10.1016/j.resinv.2026.101509Fractal-dimension–based quantification of CT micronodules for classifying borderline pneumoconiosis
Noboru Niki, Yoshiki Kawata, Yasutaka Nakano, Hiroaki Sakai et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101521Progressive fibrotic interstitial lung disease emerging after pulmonary tuberculosis: a retrospective observational study
Yasuhiro Ito, Seiichi Miwa, Tomoko Oshima, Eriko Iwaizumi et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101516Bronchoalveolar lavage fluid cytokine-based clustering identifies prognostically relevant cytokine phenotypes across interstitial lung diseases
Kazuhiro Kurasawa, Ayae Tanaka, Tomoyuki Miyao, Wataru Fujii et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101511Patient–physician communication and shared decision-making in interstitial lung disease care: A mixed-method study based on a patient community survey
Keishi Sugino, Yuto Kinoshita, Yuta Fukai, Kazuyuki Miyamura et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101519Serum GDF15 adds prognostic value to forced vital capacity in fibrotic interstitial lung disease
Yuzo Suzuki, Katsuhiro Yoshimura, Kazutaka Mori, Masato Kono et al.
2026-11 · DOI: 10.1016/j.resinv.2026.101510The value of simplicity in clinical practice guidelines. The example of antibiotic recommendations for acute COPD exacerbations
Carl Llor
2026-09 · DOI: 10.1016/j.resinv.2026.101502Nintedanib for non-IPF progressive pulmonary fibrosis: A systematic review and narrative synthesis of real-world effectiveness and safety
Narat Srivali, Federica De Giacomi
2026-09 · DOI: 10.1016/j.resinv.2026.101492From guideline to practice: Toward person-centered care for multimorbid patients with chronic obstructive pulmonary disease
Seiichi Kobayashi, Manabu Ono, Masatsugu Ishida, Hikari Satoh et al.
2026-09 · DOI: 10.1016/j.resinv.2026.101500Investigation of factors affecting the accuracy of portable monitors in Japanese professional drivers with suspected obstructive sleep apnea
Masako Ueyama, Hiroyuki Kokuto, Shoji Kudoh, Hiroshi Kimura et al.
2026-09 · DOI: 10.1016/j.resinv.2026.101481Management of drug-induced interstitial lung disease in the era of evolving lung cancer therapies: A mini-review
Taeka Naraoka, Toshiyuki Sumi
2026-09 · DOI: 10.1016/j.resinv.2026.101494Krueppel-like factors transcriptionally regulate idiopathic pulmonary fibrosis
Aritra Bhattacharyya, Alak Kumar Shyamal
2026-09 · DOI: 10.1016/j.resinv.2026.101488Integration of closed-loop fully-automated AI model with clinician assessment for lung nodule stratification: A multi-reader study
Ahmed Taha, Fayez Kheir
2026-09 · DOI: 10.1016/j.resinv.2026.101507Reviews
Community Reviews
Version History
October 10, 2026 at 2:40 am
October 2, 2026